Insider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 50,000 Shares of Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 50,000 shares of the stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $7.11, for a total value of $355,500.00. Following the completion of the transaction, the executive vice president now owns 344,683 shares of the company’s stock, valued at approximately $2,450,696.13. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Valerie Morisset also recently made the following trade(s):

• On Tuesday, July 9th, Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.66, for a total transaction of $39,500.46.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.76, for a total transaction of $338,000.00.

Eliem Therapeutics Trading Down 1.4 %

NASDAQ:ELYM traded down $0.10 during trading hours on Thursday, hitting $7.07. 126,062 shares of the stock traded hands, compared to its average volume of 469,389. The firm has a 50 day moving average price of $7.93 and a 200 day moving average price of $4.78. The firm has a market cap of $210.33 million, a price-to-earnings ratio of -13.34 and a beta of -0.33. Eliem Therapeutics, Inc. has a fifty-two week low of $2.35 and a fifty-two week high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Eliem Therapeutics stock. Cerity Partners LLC acquired a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned about 0.05% of Eliem Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 69.76% of the stock is owned by hedge funds and other institutional investors.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.